ImmuPharma plc (LON:IMM – Get Free Report) reached a new 52-week low on Wednesday. The company traded as low as GBX 2.80 and last traded at GBX 2.96, with a volume of 3,759,808 shares changing hands. The stock had previously closed at GBX 3.13.
ImmuPharma Price Performance
The firm has a market capitalization of £18.51 million, a price-to-earnings ratio of -3.57 and a beta of 3.02. The stock has a fifty day moving average of GBX 3.60 and a two-hundred day moving average of GBX 4.62.
ImmuPharma (LON:IMM – Get Free Report) last announced its earnings results on Tuesday, September 15th. The company reported GBX (0.84) EPS for the quarter. ImmuPharma had a negative return on equity of 559.87% and a net margin of 3,519.56%. On average, research analysts forecast that ImmuPharma plc will post -339.00 EPS for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
- Why Apple Stock Looks Like a Safe Haven After the Midterms
- IonQ Raised the Bar, But 3 Quantum Rivals Face Tough Questions
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
